Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

NIH 9 INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 9 Sarcoma 4 Gastrointestinal 3 Thoracic 2 Genitourinary 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Docetaxel 229 Radiotherapy 206 Magnetic Resonance Spectroscopy 204 Radiosurgery 176 Gemcitabine 155 pembrolizumab 151 Nivolumab 147 enzalutamide 140 Prednisone 129 Cisplatin 123 Leuprolide 119 Androgen Antagonists 117 Abiraterone Acetate 114 Sunitinib 106 Specimen Handling 94 Surveys and Questionnaires 91 Goserelin 91 bicalutamide 90 Carboplatin 88 Ipilimumab 82 gallium 68 PSMA-11 80 Blood Specimen Collection 78 Everolimus 73 apalutamide 72 Radiation 71 Standard of Care 68 Biopsy 68 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66 Paclitaxel 64 Cyclophosphamide 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × cediranib × Genitourinary × Clear all

NCT03741426 2023-06-07

WIRE

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡